Powering Health, Elevating Trust, Advancing Life: A Softgel CDMO Redefining Global Healthcare

With a refreshed identity and expanded presence in the Americas, Softgel Healthcare is setting a new standard for trust, speed, and collaboration.

Powering Health. Elevating Trust. Advancing Life.

For Softgel Healthcare, this is more than a slogan — it is a declaration of intent. After nearly two decades of leadership in softgel development and manufacturing, the company is unveiling a new narrative that reflects both its heritage and its future: one defined by transparency, speed, and integrity.

In a global healthcare landscape where complexity is the norm, Softgel Healthcare believes that innovation should not be slowed by boundaries. Each capsule delivered is more than a product. It is a promise, of safety, trust, and care — that ultimately reaches patients worldwide.

From Strong Foundations to a Global Presence

Headquartered in Chennai, India, Softgel Healthcare is part of the Madras Pharma Group, one of India’s top three contract manufacturers with a 40+ year legacy in healthcare. The group operates eight state-of-the-art manufacturing sites and employs more than 3,000 professionals, covering a full range of dosage forms.

Within this ecosystem, Softgel Healthcare has become the group’s dedicated softgel specialist, building 20+ years of expertise, more than 300 stable formulations, and an output of over 2 billion capsules annually. The company’s global ambitions are further reinforced by the backing of Everstone Capital, a leading private-equity investor supporting Softgel’s expansion in the CDMO segment.

Expanding Reach in the Americas

As part of its new chapter, Softgel Healthcare is expanding its presence in the Americas. This step is not simply geographic, it represents a deeper commitment to being closer to customers, faster in response, and more aligned with regional markets.

For the many partners across North and Latin America, this expansion means:

• Direct access to expertise across development, regulatory, and scale-up.
• Time zone alignment for improved collaboration.
• Faster delivery and greater support for local product launches.

The Americas team embodies Softgel’s approach: to serve not only as a CDMO, but as a true partner in possibility.

From Development to Distribution: The Prodose Advantage

Softgel Healthcare’s global reach is strengthened by Prodose, its fully owned U.S. subsidiary for OTC and nutraceutical packaging and distribution. Headquartered in Ronkonkoma, New York, with a 106,000 sq. ft. facility and 13 high-speed packaging lines, Prodose offers final-mile packaging and distribution for softgels, tablets, gummies, probiotics, and more.

Together, Softgel Healthcare and Prodose provide an end-to-end solution: from formulation and large-scale manufacturing in India, to compliant, market-ready packaging and direct distribution in the United States. This dual-site model ensures that brands gain speed to market, scalability, and regulatory confidence — all without compromising quality or cost.

With the combined capabilities of Softgel Healthcare and Prodose, partners can move seamlessly from concept to consumer, reducing time to launch and securing their place on retail shelves.

Trust and Quality at Scale

Quality is not a claim; it is a measurable reality. With a strong GMP history and approvals from U.S. FDA, EU authorities, ANVISA, and GCC, Softgel Healthcare undergoes 40–50 inspections annually — a testament to its regulatory excellence and operational transparency.

Every production cycle is safeguarded by rigorous quality systems: automated high-speed machines, automated visual inspection, and full serialization for bottles and blisters. With capabilities of 300 million high-potent capsules per year, the company combines speed with uncompromising quality, ensuring every capsule meets the highest standards.

The company’s upcoming manufacturing facility will enable a dual-source strategy, providing inherent supply-chain risk mitigation and continuity for global partners.

A New Narrative for a New Era

Softgel Healthcare’s refreshed identity is about more than aesthetics. It signals a renewed commitment to what defines the company:

• Transparency in every partnership.
• Speed without compromise on quality.
• Integrity at the core of every process.

As the company prepares to unveil its new chapter at CPHI Europe 2025, the message is clear: Softgel Healthcare, together with Prodose, is not just redefining what a CDMO can be. It is shaping the future of healthcare collaboration.

 Powering health. Elevating trust. Advancing life.

For more information, visit softgelhealthcare.com and follow Softgel Healthcare on LinkedIn.